Maze Therapeutics Files S-1/A for IPO

TL;DR

Maze Therapeutics just filed an S-1/A for their IPO. Get ready for biotech.

AI Summary

Maze Therapeutics, Inc. filed an S-1/A amendment on January 27, 2025, for its initial public offering. The company, incorporated in Delaware, is seeking to register an unspecified number of shares. Maze Therapeutics, Inc. is a biotechnology company focused on biological products, with its principal executive offices located at 171 Oyster Point Boulevard, Suite 300, South San Francisco, California.

Why It Matters

This filing indicates Maze Therapeutics is moving forward with its plan to become a publicly traded company, which could provide significant capital for its research and development efforts in the biotechnology sector.

Risk Assessment

Risk Level: medium — As a pre-IPO company in the biotechnology sector, Maze Therapeutics faces inherent risks related to clinical trials, regulatory approvals, and market acceptance of its products.

Key Numbers

• 333-284164 — SEC File Number (Identifies the specific SEC registration)
• 2836 — SIC Code (Indicates industry classification (Biological Products))

Key Players & Entities

• Maze Therapeutics, Inc. (company) — Filer of the S-1/A
• January 27, 2025 (date) — Filing date of the S-1/A
• Delaware (jurisdiction) — State of incorporation
• 171 Oyster Point Boulevard, Suite 300 South San Francisco, California 94080 (address) — Principal executive offices
• Jason Coloma, Ph.D. (person) — Chief Executive Officer
• Effie Toshav, Esq. (person) — Counsel for the registrant
• Amanda Rose, Esq. (person) — Counsel for the registrant
• Ryan Mitteness, Esq. (person) — Counsel for the registrant
• Chelsea Ande (person) — Counsel for the registrant

FAQ

Key Financial Figures

• $15.00 — ial public offering price to be between $15.00 and $17.00 per share. We have applied
• $17.00 — offering price to be between $15.00 and $17.00 per share. We have applied to list ou
• $150 million — 1 to Shionogi for an upfront payment of $150 million and the potential for additional milest

Filing Documents

• d769642ds1a.htm (S-1/A) — 2206KB
• d769642dex11.htm (EX-1.1) — 213KB
• d769642dex31.htm (EX-3.1) — 124KB
• d769642dex41.htm (EX-4.1) — 19KB
• d769642dex51.htm (EX-5.1) — 11KB
• d769642dex104.htm (EX-10.4) — 366KB
• d769642dex105.htm (EX-10.5) — 115KB
• d769642dex1011.htm (EX-10.11) — 15KB
• d769642dex1012.htm (EX-10.12) — 17KB
• d769642dex1013.htm (EX-10.13) — 16KB
• d769642dex231.htm (EX-23.1) — 1KB
• d769642dexfilingfees.htm (EX-FILING FEES) — 15KB
• g769642g01a13.jpg (GRAPHIC) — 133KB
• g769642g02g02.jpg (GRAPHIC) — 212KB
• g769642g05f43.jpg (GRAPHIC) — 588KB
• g769642g05g05.jpg (GRAPHIC) — 367KB
• g769642g1224171233822.jpg (GRAPHIC) — 1KB
• g769642g13a01.jpg (GRAPHIC) — 154KB
• g769642g21j92.jpg (GRAPHIC) — 3KB
• g769642g30x67.jpg (GRAPHIC) — 35KB
• g769642g31l38.jpg (GRAPHIC) — 114KB
• g769642g55f74.jpg (GRAPHIC) — 57KB
• g769642g62f25.jpg (GRAPHIC) — 63KB
• g769642g66t55.jpg (GRAPHIC) — 32KB
• g769642g72h13.jpg (GRAPHIC) — 35KB
• g769642g72u41.jpg (GRAPHIC) — 28KB
• g769642g74a05.jpg (GRAPHIC) — 120KB
• g769642g76l04.jpg (GRAPHIC) — 54KB
• g769642g77q77.jpg (GRAPHIC) — 33KB
• g769642g81q05.jpg (GRAPHIC) — 39KB
• g769642g94f07.jpg (GRAPHIC) — 108KB
• g769642g96l94.jpg (GRAPHIC) — 66KB
• g769642g98g45.jpg (GRAPHIC) — 42KB
• g769642g98o36.jpg (GRAPHIC) — 31KB
• 0001193125-25-012638.txt ( ) — 6282KB

Risk factors

Risk factors 15 Special note regarding forward-looking statements 82

Use of proceeds

Use of proceeds 85 Dividend policy 87 Capitalization 88

Managements discussion and analysis of financial condition and results of operations

Managements discussion and analysis of financial condition and results of operations 94

Business

Business 115 Management 161

Executive compensation

Executive compensation 174 Certain relationships and related party transactions 189 Principal stockholders 193

Description of capital stock

Description of capital stock 196 Shares eligible for future sale 202 Material U.S. federal income tax consequences to non-U.S. holders 204

Underwriting

Underwriting 209 Legal matters 221 Experts 221 Where you can find additional information 221 Index to financial statements F-1 Through and including, 2025 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription . Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or the time of any sale of shares of our common stock. i Table of Contents For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. ii Table of Contents Prospectus summary This summary highlights selected information contained elsewhere in this prospectus and does not contain

View Full Filing

View this S-1/A filing on SEC EDGAR